Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS Statin medications, most commonly prescribed to reduce lipid levels and prevent cardiovascular disease, may be associated with longer survival times of patients with cancer. However, the association of statins with outcomes of patients with pancreatic adenocarcinoma is not clear. METHODS We analyzed the association of statin use before a diagnosis of pancreatic cancer with survival times of 648 participants in the Nurses’ Health Study and Health Professionals Follow‐up Study who were diagnosed with pancreatic adenocarcinoma from 2000 through 2013. We estimated hazard ratios (HRs) for overall mortality using Cox proportional hazards models with adjustment for potential confounders. We assessed the temporal association between prediagnosis statin use and cancer survival by 2‐year lag periods to account for a possible latency period between statin use and cancer survival. RESULTS Regular statin use before diagnosis of pancreatic cancer was associated with modestly prolonged survival compared with nonregular use (adjusted HR, 0.82; 95% CI, 0.69–0.97; P = .02). A 1‐month longer median survival was observed in regular statin users compared with nonregular users. Regular statin use within the 2 years prior to cancer diagnosis was most strongly associated with longer survival. We observed no statistically significant effect modification by smoking status, body mass index, diabetes, or cancer stage (all Pinteraction > .53). Regular statin use before diagnosis was similarly associated with survival in the Nurses’ Health Study (HR, 0.79; 95% CI, 0.64–0.97) and Health Professionals Follow‐up Study (HR, 0.86; 95% CI, 0.63–1.15). CONCLUSIONS Regular statin use before diagnosis of pancreatic cancer was associated with modest increases in survival times in 2 large prospective cohort studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Test of the National Death Index and Equifax Nationwide Death Search
Rich-Edwards, J. W., Corsano, K. A., & Stampfer, M. J. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117191 · Cited by 530
Self-citation
Cited by
Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis
Carrer, A., Trefely, S., Zhao, S., Campbell, S. L., Norgard, R. J., Schultz, K. C., Sidoli, S., Parris, J. L. D., Affronti, H. C., Sivanand, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0567 · Cited by 313
Burden of Pancreatic Cancer: From Epidemiology to Practice
Khalaf, N., El-Serag, H. B., Abrams, H. R., & Thrift, A. P. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.054 · Cited by 308
Self-citationHao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55
Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis
Tamburrino, D., Crippa, S., Partelli, S., Archibugi, L., Arcidiacono, P. G., Falconi, M., & Capurso, G. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.008 · Cited by 54
Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1953136 · Cited by 22
Metadata
- Authors
- Hamada, T., Khalaf, N., Yuan, C., Morales-Oyarvide, V., Babic, A., Nowak, J. A., Qian, Z. R., Ng, K., Rubinson, D. A., Kraft, P., Giovannucci, E. L., Stampfer, M. J., Fuchs, C. S., Ogino, S., & Wolpin, B. M.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 16
- Issue
- 8
- Pages
- 1300-1306.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2789190706
- Cited by
- 25
- References
- 2
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.